Revolution Medicines Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
21.0%projected annual EPS growth
Analyst Coverage
21analysts covering
FY Revenue (est.)
$139.2Mnext fiscal year
FY EPS (est.)
-$9.56next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 4 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Daraxonrasib (RMC-6236) Phase 3 RASolute 302 Median Overall Survival (OS) Annually13.2Target: 6.7 months (chemotherapy control)
Pro Forma Cash and Marketable Securities Quarterly4BTarget: Maintain sufficient runway for late-stage clinical development
Watch Items
- NDA Submission for Daraxonrasib (RMC-6236) in previously treated metastatic PDACTrigger: Submission to global regulatory authorities, including the FDAAction: Monitor regulatory acceptance and potential priority review timeline
- Registrable Phase 3 RASolute 309 Trial InitiationTrigger: First patient dosed in doublet combination of zoldonrasib plus daraxonrasibAction: Verify trial initiation timeline in the second half of 2026
Research as of 2 Sep 2026